Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 15Lymphoid 7Breast 5Thoracic 4Genitourinary 4Dermatologic 4Sarcoma 2Plasma cell 2Other solid neoplasm 2Other hematologic neoplasm 2Head & Neck 2CNS 2Tumor-Agnostic 1Other neoplasm 1Myeloid 1Gynecologic 1

Conditions

Sarcoma 2Neoplasm Metastasis 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

Radiotherapy 137Cyclophosphamide 132Temozolomide 116Doxorubicin 99Filgrastim 68Ifosfamide 64Gemcitabine 58Etoposide 55Bevacizumab 51Imatinib Mesylate 50fludarabine phosphate 49Irinotecan 46pembrolizumab 45Peripheral Blood Stem Cell Transplantation 45pazopanib 43Magnetic Resonance Spectroscopy 42Methotrexate 40Carboplatin 40Busulfan 40Vincristine 38Surgical Procedures, Operative 37Nivolumab 37Melphalan 37Cisplatin 36Radiation 34Blood Specimen Collection 33Mycophenolic Acid 31Cyclosporine 31Docetaxel 29Trabectedin 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Pharmaceutical Preparations × Sarcoma × Clear all
NCT04138381 2023-03-27

SeliGIST

Grupo Espanol de Investigacion en Sarcomas

Phase 1/2 Unknown
30 enrolled
Sarcoma

Neoplasm Metastasis, Sarcoma, Drug-Related Side Effects and Adverse Reactions

NCT03698227 2020-07-15

OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2 Terminated
2 enrolled
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡